You are here

P&T® Journal contents for July 2006


Letter to the Editor
Reena Patel, PharmD Candidate
P&T Around the World
The authors experiment with educating diabetic patients about their illness, medications, and lifestyle changes. Knowledge scores, but not practices, improved.
Subish Palaian, MPharm, Leelavathy D. Acharya, MPharm, Padma Guru Madhva Rao, MPharm, PhD, P. Ravi Shankar MD, Nidin Mohan Nair, MPharm, and Nibu P. Nair, MPharm
Various keratinolytic, antimicrobial, and homeopathic therapies for dandruff of the scalp are presented.
Angela Sanfilippo, MD, and Joseph C. English III, MD
Meeting Highlights
The author discusses the addition of esomeprazole (Nexium) to low-dose aspirin therapy to prevent gastroduodenal and esophageal ulceration; the treatment of ulcerative colitis with MMX mesalamine (SPD-476) and infliximab (Remicade); and the use of sargramostim granulocyte–macrophage colony-stimulating factor (Leukine) for Crohn’s disease.
Walter Alexander
The author reviews Gardasil, the first vaccine against human papillomavirus (types 6, 11, 16, 18), intended to prevent cervical cancer, precancerous cervical lesions, and genital warts; extended-release bupropion (Wellbutrin XL) for Seasonal Affective Disorder (SAD); and varenicline (Chantix), an aid in smoking cessation.
Marvin M. Goldenberg, PhD, RPh, MS


David Nash, MD, MBA, discusses PhRMA’s 2006 Pharmaceutical Industry Profile, which comments on the drug industry’s commitment to research and development, providing access to medications, and ensuring relief for Hurricane Katrina victims.
David Nash, MD, MBA
Medication Errors
Matthew Grissinger, RPh, FASCP, explains how to avoid errors when attaching an intravenous fluid line to the intended port.
Matthew Grissinger, RPh, FASCP
Prescription: Washington
Stephen Barlas discusses an unintended consequence of the Medicare Part D drug benefit: how community drugstores might be shortchanged when drug plans funnel most prescription business to mail-order and big-name chain pharmacies.
Stephen Barlas
P&T presents the latest information about FDA approvals, drug indications, and devices.
Drug Forecast
The authors discuss natalizumab (Tysabri) for MS.
Sarah R. Erlanger, PharmD, and Michael T. Inzerillo, MBA, RPh